Yamakawa Hideaki, Hagiwara Eri, Kitamura Hideya, Yamanaka Yumie, Ikeda Satoshi, Sekine Akimasa, Baba Tomohisa, Okudela Koji, Iwasawa Tae, Takemura Tamiko, Kuwano Kazuyoshi, Ogura Takashi
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan;; Department of Respiratory Medicine, Tokyo Jikei University Hospital, Tokyo, Japan.
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
J Thorac Dis. 2017 Feb;9(2):362-371. doi: 10.21037/jtd.2017.02.48.
Interstitial lung disease (ILD) is frequent complication of systemic sclerosis (SSc) and mixed connective tissue disease (MCTD). The disease is heterogeneous, and its outcome is unpredictable. Some patients have severe and progressive deterioration of ILD, which is the leading cause of mortality. We aimed to determine whether serum levels of Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) correlate with SSc/MCTD-associated ILD activity.
We retrospectively analyzed the medical records of 40 patients with SSc/MCTD-associated ILD: 29 patients with SSc and 11 patients with MCTD. Measurement of serum KL-6 and SP-D levels, pulmonary function tests, and high-resolution computed tomography (HRCT) performed in parallel were reviewed.
Serum KL-6 correlated positively with diffusing capacity of the lung for carbon monoxide (DLCO) (% predicted) and disease extent on HRCT, and the changes in serum levels of KL-6 were significantly related to the changes in forced vital capacity (FVC) in SSc/MCTD-associated ILD. On the other hand, multivariate logistic regression analyses with calculation of the area under the curve of the receiver-operating characteristic curve suggested that a higher serum level of SP-D was a significant predictor of FVC decline in SSc/MCTD-associated ILD.
Our study suggests that serum KL-6 can be a useful monitoring tool of SSc/MCTD-associated ILD activity. In contrast, serum SP-D may be a significant predictor of potential FVC decline in the short term.
间质性肺疾病(ILD)是系统性硬化症(SSc)和混合性结缔组织病(MCTD)的常见并发症。该疾病具有异质性,其预后不可预测。一些患者的ILD会严重且进行性恶化,这是导致死亡的主要原因。我们旨在确定血清克雷伯氏肺表面活性物质相关蛋白-6(KL-6)和表面活性蛋白-D(SP-D)水平是否与SSc/MCTD相关的ILD活动相关。
我们回顾性分析了40例SSc/MCTD相关ILD患者的病历:29例SSc患者和11例MCTD患者。对同时进行的血清KL-6和SP-D水平测量、肺功能测试以及高分辨率计算机断层扫描(HRCT)进行了回顾。
血清KL-6与肺一氧化碳弥散量(DLCO)(预测值%)和HRCT上的疾病范围呈正相关,并且在SSc/MCTD相关ILD中,血清KL-6水平的变化与用力肺活量(FVC)的变化显著相关。另一方面,通过计算受试者操作特征曲线下面积进行的多因素逻辑回归分析表明,较高的血清SP-D水平是SSc/MCTD相关ILD中FVC下降的显著预测指标。
我们的研究表明,血清KL-6可作为监测SSc/MCTD相关ILD活动的有用工具。相比之下,血清SP-D可能是短期内FVC潜在下降的显著预测指标。